Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-3939a in Solid Tumors
NCT07739966Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Jul 2030
- Countries
- 13
01
Overview
A Phase 2 trial of DS-3939 in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2026; status: recruiting.
02
Drugs
DS-3939
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07739966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739966.